Fully human immunoglobulin G1-λ monoclonal antibody.
E recombinant you mean monoclonal antibody that inhibits the height in cell activating factor for use in patients with active SLE but ot in those good severe CNS and renal involvement.
Approved for use in systemic lupus erythematous.
Benefits modest and confined to musculoskeletal and mucocutaneous systems.
Testing of the drug excluded patients with active kidney or CNS disease.
In adults with active lupis nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response and those who receive standing therapy alone (Furie R).
Belimumab May have a role in augmenting induction treatment with mycophenolate in patients with active lupus nephritis.
Not proven to be beneficial in blacks, as they made up too small of the study population.
Administered by intravenous infusion.
Inhibits biological actvity of soluble human B lymphocyte stimulator, associated with SLE.
Utilized with standard therapy including corticosteroids, antimalarials, immunosuppressive agents and NSAIDs.
Adverse reactions include: nausea, diarrhea, insomnia, depression and migraine headaches.
And a randomized double-blind trial of belimumab plus standard immunosuppressive therapies compared to placebo in patients with active lupus nephritis: patients with belimumab were for 1.3 times more likely to have primary efficacy response and 1.5 times more likely to have a complete renal response than those who receive placebo.